Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Impala Nordic: OncoZenge - Report Comment: Recruitment sets the timetable

ONCOZPress release2026-11-12 13:00

Impala Nordic has published a coverage comment on OncoZenge AB (publ) following the company's interim report for the third quarter of 2026.
The quarter changed the company's financial position. Cash rose from SEK 0.7m at the half-year mark to SEK 24.3m and the equity ratio from 36.5 to 55.3 percent, after a rights issue subscribed to approximately 92 percent in which the guarantee was never called. Sichuan Yangtian subscribed for its full pro rata entitlement and remains the largest owner at 19.7 percent.
Nine hospitals are now recruiting in the pivotal Phase III BEAM-Pain trial, and the company has received several written, non-binding offers from potential licensees ahead of the readout. Recruitment has run slower than planned, and completion of the trial has moved into 2027.

Click here to read the report comment

For additional information, please contact:


Ylber Rexhepi, CEO Impala Nordic
ylber@impalanordic.se

About Impala Nordic


Impala Nordic provides equity research, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.

The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.

Bifogade filer


OncoZenge Report Comment 2026 11 12